Welcome to the international HTA database

Showing [18422 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brivaracetam - addendum to commission A16-08]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brivaracetam - benefit assessment according to §35a Social Code Book V]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brodalumab (plaque psoriasis) – benefit assessment according to §35a Social Code Book V]
2008	Committee for New Health Technology Assessment (CNHTA)	[Bronchial provocation test]
2021	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Bronchial thermoplasty in severe asthma]
2012	Basque Office for Health Technology Assessment (OSTEBA)	[Budget impact analysis of a telemedicine procedure in quality assurance programs for spirometry in patients with COPD]
2012	Institut national d'excellence en sante et en services sociaux (INESSS)	[Budget impact analysis of increasing kidney transplantation in Québec]
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Building planning and infection control: hand hygiene dispensers and individual bathrooms in residential and long-term care centres]
2009	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bupropion, mirtazapine, and reboxetine in the treatment of depression]
2010	National Evidence-based Healthcare Collaborating Agency (NECA)	[Burden of irritable bowel syndrome in Korea]
2013	Haute Autorite de sante (HAS)	[Bypass prostheses]
2012	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Bypass surgery performed with or without the use of heart-lung machine]
2011	Committee for New Health Technology Assessment (CNHTA)	[C-11-acetate positron emission tomography, positron emission tomography/computed tomography]
2020	Andalusian Health Technology Assessment Area (AETSA)	[C-Reactive Protein point-of-care testing (CRP-POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections]
2012	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabazitaxel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cabazitaxel, abiraterone and enzalutamide in metastatic castration-resistant prostate cancer not responding to docetaxel]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabozantinib - assessment according to section 35a (paragraph 1, sentence 10) Social Code Book V (dossier assessment)]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabozantinib (renal cell carcinoma) - addendum to order A16-69]
2018	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabozantinib (renal cell carcinoma) - benefit assessment according to §35a Social Code Book V]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2005	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Caesarean section on maternal request: a health technology assessment]
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Calreticulin gene mutation testing in myeloproliferative neoplasms]
2011	Committee for New Health Technology Assessment (CNHTA)	[Camera manipulating robot assisted endoscopic surgery]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Canagliflozin, empagliflozin and dapagliflozin (SGLT-2) for patients with type 2 diabetes]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Canagliflozin, empagliflozin and dapagliflozin in type 2 diabetes patients]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Canagliflozin: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Canagliflozin/metformin. Benefit assessment according to section 35a Social Code Book V (dossier assessment)]
2013	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Canaloplasty for open angle glaucoma]
2001	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Cancer of the colon and rectum - diagnosis and screening]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cannabinoids in patients with autism spectrum disorders]
2005	Andalusian Health Technology Assessment Area (AETSA)	[Cannabis therapeutic utility]
2020	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2007	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Capsule endoscopies of the small intestine - a health technology assessment]
2010	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Cardiac contractility modulation for heart failure- 2nd Update 2010]
2010	Haute Autorite de sante (HAS)	[Cardiac markers in coronary disease and heart failure in outpatient medicine]
2006	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Cardiac rehabilitation - a health technology assessment: evidence from the literature and the DANREHAB trial]
2005	Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS )	[Cardiac resynchronization therapy: multi-site pacemaker use]
2010	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Cardiac resynchronization therapy. Economic evaluation]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Cardiac surgery registry. An international review]
2009	Committee for New Health Technology Assessment (CNHTA)	[Cardio detect(h-FABP)]
2013	Andalusian Health Technology Assessment Area (AETSA)	[CardioWest™ TAH-t. Total artificial heart]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Carfilzomib - assessment according to §35a (para. 1, sentence 10) Social Code Book V]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Carfilzomib (multiple myeloma; combination with dexamethasone alone) – assessment according to § 35a (para.1, sentence 10) Social Code Book V]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Carfilzomib (multiple myeloma) – benefit assessment according to §35a Social Code Book V]
2008	Committee for New Health Technology Assessment (CNHTA)	[Caries diagnosis with laser fluorescence(Diagnodent)]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Carotid echo doppler for plaque area measurement in cardiovascular risk stratification]
2011	Basque Office for Health Technology Assessment (OSTEBA)	[Case and control study: efficiency of psychoeducational treatment of the overload experienced by family members of bipolar patients]
2012	The Swedish Council on Health Technology Assessment (SBU)	[Case finding, diagnosis and follow up of patients with affective disorders]
2012	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Catalan arthroplasty register. 2nd report (data 2005-2010)]
2010	The Swedish Council on Health Technology Assessment (SBU)	[Catheter ablation for atrial fibrillation (update)]
2005	The Swedish Council on Health Technology Assessment (SBU)	[Catheter ablation of atrial fibrillation - early assessment briefs (Alert)]
2012	Institute for Clinical Effectiveness and Health Policy (IECS)	[Catheter-directed mechanical thrombolysis in thromboembolic disease]
2008	Committee for New Health Technology Assessment (CNHTA)	[CBFB/MYH11 rearrangement, Quantification [Real-time RT-PCR]]
2009	Committee for New Health Technology Assessment (CNHTA)	[CD4 lymphocyte activity (bioluminescent assay)]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ceftazidime/avibactam in severe infections]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Central auditory processing disorder diagnosis]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cerebrospinal fluid neurotransmitter screening in encephalopathies]
2015	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceritinib - benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceritinib (lung cancer): Addendum to Commission A16-62]
2016	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceritinib (lung cancer): benefit assessment according to §35a Social Code Book V; expiry of the decision
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ceritinib (non-small cell lung cancer) – benefit assessment according to §35a Social Code Book V]
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ceritinib for the treatment of ALK-positive metastatic non-small cell lung cancer]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ceritinib in lung cancer]
2017	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cerliponase alfa (neuronal ceroid lipofuscinosis) - assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cerliponase alfa in neuronal ceroid lipofuscinosis type 2]
2010	Haute Autorite de sante (HAS)	[Cervical length measurement with transvaginal ultrasonography to predict spontaneous preterm birth]
2011	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cessation of smoking in essential hypertension - Rapid report]
2006	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Cetuximah given in combination for patients with colorectal cancer]
2014	Institut national d'excellence en sante et en services sociaux (INESSS)	[Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up]
2018	Basque Office for Health Technology Assessment (OSTEBA)	[Checklist for ethical and legal domains analysis]
2012	Institute for Clinical Effectiveness and Health Policy (IECS)	[Chemoembolization and radioembolization for the treatment of liver metastases]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Choice-based conjoint analysis: pilot project to identify, weight, and prioritize multiple attributes in the indication "hepatitis C"]
2014	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cholic acid: assessment according to section 35a (paragraph 1, sentence 10) Social Code Book V (dossier assessment)]
2012	Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[ChondroCelect® in patients with knee cartilage injury]
2013	Institute for Clinical Effectiveness and Health Policy (IECS)	[Chromosomal microarrays for the etiologic diagnosis in patients with intellectual disability, developmental delay or autism spectrum]
2010	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	[Chronic fatigue syndrome: state of the evidence and assessment of intervention modalities in Quebec]
2002	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Chronic hepatitis C. Combination therapy IFN and ribavirin]
2010	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Chronic low back pain: the appropriate use of diagnostic imaging procedures]
2005	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Chronic periodontitis - prevention, diagnosis and treatment]
2014	The Swedish Council on Health Technology Assessment (SBU)	[Chronic ulcers in the elderly – prevention and treatment]
2013	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cidofovir for the treatment of recurrent respiratory papillomatosis]
2010	The Swedish Council on Health Technology Assessment (SBU)	[Cilostazol for treatment of intermittent claudication]
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Circulating tumour cells in breast cancer: clinical use of the CellSearch® test]
2010	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Classification of disease severity for neuro- and trauma rehabilitation Part 3: Status quo in Austria]
2008	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Clavicular fractures - a systematic review about efficacy and safety of different treatment options]
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical Efectiveness of Newborn Screening for Inborn Errors of Metabolism by MS/ MS. Update and pilot study assessment: Maple Syrup Urine Disease; Isovaleric Acidaemia; Homocystinuria]
2012	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Clinical effectiveness and cost-effectiveness of central venous catheters treated with minocycline and rifampicin in preventing bloodstream infections in intensive care patients]
2014	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Clinical effectiveness and cost-effectiveness of fissure sealants in children and adolescents with a high caries risk]
2017	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical effectiveness and cost-effectiveness of non-invasive telemonitoring on patients with heart failure]
2013	National Evidence-based Healthcare Collaborating Agency (NECA)	[Clinical effectiveness and safety of robotic surgery]
2005	Unit of Health Economics and Technology Assessment in Health Care (HunHTA)	[Clinical effectiveness of carvedilol in comparison to -blockers, systematic review of the clinical and economic literature]
2005	Unit of Health Economics and Technology Assessment in Health Care (HunHTA)	[Clinical effectiveness of indapamide; systematic review of the clinical and economic literature]
2007	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry. Systematic Review]
2013	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry: Maple Syrup Urine Disease, Homocystinuria, Glutaric Aciduria Type I, Isovaleric Acidaemia, Long-chain 3-Hydroxyacyl CoA Dehydrogenase Deficiency]
2015	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part III: carnitine uptake deficiency (CUD); short-chain acyl-CoA dehydrogenase deficiency (SCADD); very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2015	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part IV: Beta-kethiolase deficiency (BKT); 3-Hydroxy-3-methyl glutaric aciduria (HMG)]
2015	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part IV: β-ketothiolase deficiency (BKT); 3-hydroxy-3-methyl glutaric aciduria (HMG)]
2014	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism. Part II: Methylmalonic acidemia, Propionic acidemia, Tyrosinemia type I]
2018	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for severe combined immunodeficiency]